These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 30055293)

  • 1. Aberrant cardiolipin metabolism is associated with cognitive deficiency and hippocampal alteration in tafazzin knockdown mice.
    Cole LK; Kim JH; Amoscato AA; Tyurina YY; Bay R H; Karimi B; Siddiqui TJ; Kagan VE; Hatch GM; Kauppinen TM
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3353-3367. PubMed ID: 30055293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.
    Mejia EM; Zegallai H; Bouchard ED; Banerji V; Ravandi A; Hatch GM
    J Biol Chem; 2018 May; 293(20):7564-7577. PubMed ID: 29563154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
    Russo S; De Rasmo D; Signorile A; Corcelli A; Lobasso S
    Sci Rep; 2022 Nov; 12(1):19847. PubMed ID: 36400945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome.
    Russo S; De Rasmo D; Rossi R; Signorile A; Lobasso S
    Sci Rep; 2024 Jun; 14(1):13655. PubMed ID: 38871974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiolipin deficiency elevates susceptibility to a lipotoxic hypertrophic cardiomyopathy.
    Cole LK; Mejia EM; Sparagna GC; Vandel M; Xiang B; Han X; Dedousis N; Kaufman BA; Dolinsky VW; Hatch GM
    J Mol Cell Cardiol; 2020 Jul; 144():24-34. PubMed ID: 32418915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
    Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
    Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
    J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy.
    Hsu P; Liu X; Zhang J; Wang HG; Ye JM; Shi Y
    Autophagy; 2015 Apr; 11(4):643-52. PubMed ID: 25919711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substantial Decrease in Plasmalogen in the Heart Associated with Tafazzin Deficiency.
    Kimura T; Kimura AK; Ren M; Berno B; Xu Y; Schlame M; Epand RM
    Biochemistry; 2018 Apr; 57(14):2162-2175. PubMed ID: 29557170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac metabolic pathways affected in the mouse model of barth syndrome.
    Huang Y; Powers C; Madala SK; Greis KD; Haffey WD; Towbin JA; Purevjav E; Javadov S; Strauss AW; Khuchua Z
    PLoS One; 2015; 10(6):e0128561. PubMed ID: 26030409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tafazzin Deficiency Reduces Basal Insulin Secretion and Mitochondrial Function in Pancreatic Islets From Male Mice.
    Cole LK; Agarwal P; Doucette CA; Fonseca M; Xiang B; Sparagna GC; Seshadri N; Vandel M; Dolinsky VW; Hatch GM
    Endocrinology; 2021 Jul; 162(7):. PubMed ID: 34019639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiolipin remodeling: a regulatory hub for modulating cardiolipin metabolism and function.
    Ye C; Shen Z; Greenberg ML
    J Bioenerg Biomembr; 2016 Apr; 48(2):113-23. PubMed ID: 25432572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barth syndrome cells display widespread remodeling of mitochondrial complexes without affecting metabolic flux distribution.
    Chatzispyrou IA; Guerrero-Castillo S; Held NM; Ruiter JPN; Denis SW; IJlst L; Wanders RJ; van Weeghel M; Ferdinandusse S; Vaz FM; Brandt U; Houtkooper RH
    Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3650-3658. PubMed ID: 30251684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafazzin deficiency causes substantial remodeling in the lipidome of a mouse model of Barth Syndrome cardiomyopathy.
    Hachmann M; Gülcan G; Rajendran R; Höring M; Liebisch G; Bachhuka A; Kohlhaas M; Maack C; Ergün S; Dudek J; Karnati S
    Front Mol Med; 2024; 4():1389456. PubMed ID: 39086433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
    Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
    Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.
    Zhang J; Liu X; Nie J; Shi Y
    Autophagy; 2022 Sep; 18(9):2134-2149. PubMed ID: 34985382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiolipin-deficient cells have decreased levels of the iron-sulfur biogenesis protein frataxin.
    Li Y; Lou W; Grevel A; Böttinger L; Liang Z; Ji J; Patil VA; Liu J; Ye C; Hüttemann M; Becker T; Greenberg ML
    J Biol Chem; 2020 Aug; 295(33):11928-11937. PubMed ID: 32636300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of the cardiolipin-specific phospholipase Cld1 rescues growth and life span defects in the tafazzin mutant: implications for Barth syndrome.
    Ye C; Lou W; Li Y; Chatzispyrou IA; Hüttemann M; Lee I; Houtkooper RH; Vaz FM; Chen S; Greenberg ML
    J Biol Chem; 2014 Feb; 289(6):3114-25. PubMed ID: 24318983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased pyruvate dehydrogenase activity in Tafazzin-deficient cells is caused by dysregulation of pyruvate dehydrogenase phosphatase 1 (PDP1).
    Liang Z; Ralph-Epps T; Schmidtke MW; Kumar V; Greenberg ML
    J Biol Chem; 2024 Mar; 300(3):105697. PubMed ID: 38301889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
    Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
    Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.